These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 25660387

  • 1. Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes.
    Sharma P, Juhn A, Houston SK, Fineman M, Chiang A, Ho A, Regillo C.
    Am J Ophthalmol; 2015 May; 159(5):861-7.e2. PubMed ID: 25660387
    [Abstract] [Full Text] [Related]

  • 2. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.
    Chatziralli I, Theodossiadis G, Parikakis E, Datseris I, Theodossiadis P.
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555
    [Abstract] [Full Text] [Related]

  • 3. Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole.
    Quezada-Ruiz C, Pieramici DJ, Nasir M, Rabena M, Steinle N, Castellarin AA, Dhoot D, Couvillion S, See RF, Avery RL.
    Retina; 2015 Jun; 35(6):1144-50. PubMed ID: 25961122
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. ASSESSMENT OF ANATOMICAL AND FUNCTIONAL OUTCOMES WITH OCRIPLASMIN TREATMENT IN PATIENTS WITH VITREOMACULAR TRACTION WITH OR WITHOUT MACULAR HOLES: Results of OVIID-1 Trial.
    Tadayoni R, Holz FG, Zech C, Liu X, Spera C, Stalmans P.
    Retina; 2019 Dec; 39(12):2341-2352. PubMed ID: 30308558
    [Abstract] [Full Text] [Related]

  • 7. Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes?
    Hager A, Seibel I, Riechardt A, Rehak M, Joussen AM.
    Br J Ophthalmol; 2015 May; 99(5):635-8. PubMed ID: 25403647
    [Abstract] [Full Text] [Related]

  • 8. Assessment of intravitreal ocriplasmin treatment for vitreomacular traction in clinical practice.
    Schumann RG, Langer J, Compera D, Luedtke K, Schaumberger MM, Kreutzer T, Mayer WJ, Wolf A, Priglinger SG.
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2081-2089. PubMed ID: 28755165
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bilateral vitreomacular traction resolved with a single intravitreal ocriplasmin injection.
    Katz RS.
    Ophthalmic Surg Lasers Imaging Retina; 2014 Nov; 45(3):239-42. PubMed ID: 24708167
    [Abstract] [Full Text] [Related]

  • 12. Functional improvement assessed by multifocal electroretinogram after Ocriplasmin treatment for vitreomacular traction.
    Rossi S, Testa F, Melillo P, Orrico A, Della Corte M, Simonelli F.
    BMC Ophthalmol; 2016 Jul 18; 16():110. PubMed ID: 27430356
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The Portuguese Experience with Ocriplasmin in Clinical Practice.
    Figueira J, Martins D, Pessoa B, Ferreira N, Meireles A, Sampaio A, Carneiro Â, Vaz F, Nascimento J, Moreno N, Roque J, Domingues M, Flores R, Teixeira C, Conde E, Henriques F, Proença H, Pita Negrão J, Barbosa M, Silva R, Vaz-Pereira S, Pereira Neves P, Gomes N, Raimundo M, Jetrea Study Group.
    Ophthalmic Res; 2016 Jul 18; 56(4):186-192. PubMed ID: 27438077
    [Abstract] [Full Text] [Related]

  • 17. Ocriplasmin-Induced Macular Hole Closure in the Absence of Vitreomacular Adhesion Release.
    Modi YS, Singh RP.
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun 18; 46(6):677-9. PubMed ID: 26114851
    [Abstract] [Full Text] [Related]

  • 18. [Initial Clinical Experiences Using Ocriplasmin for the Treatment of Vitreomacular Traction with or without a Macular Hole].
    Lenk J, Matthé E, Ventzke S, Pillunat LE, Sandner D.
    Klin Monbl Augenheilkd; 2018 Jan 18; 235(1):73-80. PubMed ID: 28282697
    [Abstract] [Full Text] [Related]

  • 19. Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole.
    Gandorfer A, Benz MS, Haller JA, Stalmans P, Pakola SJ, Girach A, Kampik A, Toth CA, Jaffe GJ, MIVI-TRUST Study Group.
    Retina; 2015 Jun 18; 35(6):1151-7. PubMed ID: 25741816
    [Abstract] [Full Text] [Related]

  • 20. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
    Maier M, Abraham S, Frank C, Lohmann CP, Feucht N.
    Ophthalmologe; 2017 Feb 18; 114(2):148-154. PubMed ID: 27444007
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.